CELLECTAR BIOSCIENCES INC (CLRB) Stock News

NASDAQ:CLRB - US15117F8077 - Common Stock

4.98 USD

+0.2 (+4.18%)

Last: 9/4/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CLRB Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

2 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

22 days ago - By: The Motley Fool

Cellectar Cuts Q2 Losses and Expenses

22 days ago - By: Benzinga

A Peek at Cellectar Biosciences's Future Earnings

9 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

9 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

22 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

22 days ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

22 days ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

3 months ago - By: Zacks Investment Research - Mentions: ANIX

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

3 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules